Isomorphic Labs

Isomorphic Labs builds computational systems for protein prediction and molecular modelling to accelerate drug discovery.

London, UK—Founded 2021—Website

$2.5BTotal raised

London-based drug discovery startup spun out from Google DeepMind, developing artificial intelligence systems for molecular modelling and pharmaceutical research.

Founders

Sir Demis Hassabis

Founder and CEO

Demis Hassabis

Co-founder

Demis serves as chief executive officer of Google DeepMind and chief scientist at Alphabet, alongside founding Isomorphic Labs. He previously held leadership roles at Google DeepMind and various games studios.

Investors

Other11 May 2026
$2.0B
T
ThriveLeadFollow-on
A
AlphabetFollow-on
Other31 March 2025
£459M
T
ThriveLead
GV
A
Alphabet

Funding history

Other11 May 2026

$2.0B

Isomorphic Labs enters advanced talks to raise over $2bn from Thrive Capital and Alphabet.

Thrive Capital is set to lead the financing round, which would value the artificial intelligence drug discovery startup at more than triple its previous raise.

Other31 March 2025

£459M

Isomorphic Labs secures £458.6m in a funding round led by Thrive Capital to advance its artificial intelligence drug design engine.

The financing round was led by Thrive Capital with backing from GV and Alphabet.